Top 10 Performing Stocks To Own Right Now

LISTEN TO ARTICLE 3:18 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

BOE Technology Group Co.’s stock market reversal is dramatic even by China’s outsized standards. It took less than a year for the Apple Inc. supplier to go from one of the nation’s best-performing stocks to among its worst — a precipitous selloff that may not be over.

China’s largest maker of screens for TVs and phones shed more than 32 percent of its value this year, the steepest decline among the 50 biggest companies listed in Shanghai and Shenzhen. That was prompted by ballooning supply and plunging prices for the large screens that comprise most of its business. Even earning a coveted spot on Apple’s list of top 200 suppliers couldn’t overcome fears that demand-supply imbalances will persist, analysts say.

Top 10 Performing Stocks To Own Right Now: Interactive Brokers Group, Inc.(IBKR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Interactive Brokers Group (NASDAQ:IBKR) had its price target cut by SunTrust Banks to $71.00 in a research report sent to investors on Wednesday. They currently have a $65.34 rating on the financial services provider’s stock. SunTrust Banks also issued estimates for Interactive Brokers Group’s Q3 2018 earnings at $0.54 EPS, Q4 2018 earnings at $0.59 EPS, FY2018 earnings at $2.34 EPS, Q1 2019 earnings at $0.60 EPS, Q2 2019 earnings at $0.64 EPS, Q3 2019 earnings at $0.66 EPS, Q4 2019 earnings at $0.70 EPS and FY2019 earnings at $2.60 EPS.

  • [By Stephan Byrd]

    Interactive Brokers Group (NASDAQ: IBKR) and Charles Schwab Co. Common Stock (NYSE:SCHW) are both large-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

  • [By Joseph Griffin]

    Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

    Get Interactive Brokers Group alerts:

    What Could Attract Investors to Interactive Brokers (finance.yahoo.com) Reviewing Charles Schwab (SCHW) and Interactive Brokers Group (IBKR) (americanbankingnews.com) Interactive Brokers Group (IBKR) Presents At Sandler O’Neill’s Global Exchange And Brokerage Conference – Slideshow (seekingalpha.com) Should You Invest In The Financial Stock Interactive Brokers Group Inc (NASDAQ:IBKR)? (finance.yahoo.com) Interactive Brokers Welcomes New Bond Disclosure Rules (finance.yahoo.com)

    Shares of Interactive Brokers Group traded up $1.20, reaching $71.38, during midday trading on Friday, according to MarketBeat Ratings. 1,131,168 shares of the company were exchanged, compared to its average volume of 859,815. The stock has a market cap of $29.39 billion, a PE ratio of 46.65, a PEG ratio of 1.65 and a beta of 0.95. Interactive Brokers Group has a one year low of $36.23 and a one year high of $80.32.

  • [By Dustin Blitchok]

    The European Union’s General Data Protection Regulation takes effect May 25, and Steve Sanders, the executive vice president of marketing and product development at Interactive Brokers (NASDAQ: IBKR), described it as the “bane of my existence.” Compliance with the regulations is taking resources from other products at the online brokerage, he said.

  • [By Max Byerly]

    Compass Point started coverage on shares of Interactive Brokers Group (NASDAQ:IBKR) in a research note published on Tuesday. The brokerage issued a neutral rating and a $74.00 price target on the financial services provider’s stock.

Top 10 Performing Stocks To Own Right Now: Park-Ohio Holdings Corp.(PKOH)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Park-Ohio (PKOH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Park-Ohio (PKOH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Park-Ohio (NASDAQ: PKOH) and Materion (NYSE:MTRN) are both small-cap industrial products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

  • [By Logan Wallace]

    Park-Ohio (NASDAQ: PKOH) and Shiloh Industries (NASDAQ:SHLO) are both small-cap industrial products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Top 10 Performing Stocks To Own Right Now: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

    Get Monotype Imaging alerts:

    Should You Be Holding Monotype Imaging Holdings Inc (NASDAQ:TYPE)? (finance.yahoo.com) Monotype Imaging Holdings Inc. (TYPE) Forecasted to Earn Q1 2019 Earnings of $0.07 Per Share (americanbankingnews.com) Monotype Partners with PKU Founder Information Industry Group to Bring Latin Typefaces to Enterprise Brands and Creative Professionals in China (finance.yahoo.com) $59.42 Million in Sales Expected for Monotype Imaging Holdings Inc. (TYPE) This Quarter (americanbankingnews.com) Introducing the Walbaum Typeface: the Restoration of a Warm and Stylish Serif Design That Has Nearly Limitless Applications (finance.yahoo.com)

    TYPE has been the topic of a number of research analyst reports. B. Riley raised shares of Monotype Imaging from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $24.50 to $31.00 in a research report on Tuesday, February 20th. Zacks Investment Research raised shares of Monotype Imaging from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research report on Tuesday, February 27th. ValuEngine raised shares of Monotype Imaging from a “sell” rating to a “hold” rating in a research report on Tuesday, February 20th. TheStreet downgraded shares of Monotype Imaging from a “b” rating to a “c+” rating in a research report on Friday, April 27th. Finally, BidaskClub downgraded shares of Monotype Imaging from a “hold” rating to a “sell” rating in a research report on Saturday, May 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Monotype Imaging presently has an average rating of “Hold” and an average p

  • [By Joseph Griffin]

    Monotype Imaging (NASDAQ:TYPE) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

  • [By Max Byerly]

    Zscaler (NASDAQ: ZS) and Monotype Imaging (NASDAQ:TYPE) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Monotype Imaging (NASDAQ:TYPE) from a sell rating to a hold rating in a research report report published on Tuesday morning.

Top 10 Performing Stocks To Own Right Now: Jazz Pharmaceuticals Inc.(JAZZ)

Advisors’ Opinion:

  • [By Keith Speights]

    But at least three of the biotechs singled out by the FDA deserve to be on another list — investors’ buy lists. Here’s why Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Jazz Pharmaceuticals (NASDAQ:JAZZ) look like great stock picks right now.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Private Capital Advisors Inc. acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, HoldingsChannel reports. The institutional investor acquired 24,200 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,170,000.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Here are some of the news headlines that may have impacted Accern’s rankings:

    Get Jazz Pharmaceuticals alerts:

    Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sle… (advfn.com) Jazz Pharmaceuticals (JAZZ) Given a $194.00 Price Target at Royal Bank of Canada (americanbankingnews.com) Analyzing Jazz Pharmaceuticals (JAZZ) & Celyad (CYAD) (americanbankingnews.com) Global Marine Pharmaceuticals Market Growing at a CAGR of 7.28% to 2022 (empowerednews.net) Physicians Unaware of Neurologic Effects Related to Obstructive Sleep Apnea, Finds Jazz Pharmaceuticals Survey (sleepreviewmag.com)

    Shares of Jazz Pharmaceuticals traded up $1.75, hitting $170.75, during trading on Friday, MarketBeat reports. 928,650 shares of the company were exchanged, compared to its average volume of 466,308. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 0.87 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $171.76. The company has a quick ratio of 2.88, a current ratio of 3.00 and a debt-to-equity ratio of 0.55.

Top 10 Performing Stocks To Own Right Now: Videocon d2h Limited(VDTH)

Advisors’ Opinion:

  • [By Logan Wallace]

    Videocon d2h (NASDAQ: VDTH) and MSG Networks (NYSE:MSGN) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

  • [By Joseph Griffin]

    Videocon d2h (NASDAQ: VDTH) and DISCOVERY COMMUNICATIONS INC. Common Stock (NASDAQ:DISCA) are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Top 10 Performing Stocks To Own Right Now: Murphy Oil Corporation(MUR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Clinton Group Inc. purchased a new stake in Murphy Oil Co. (NYSE:MUR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,491 shares of the oil and gas producer’s stock, valued at approximately $489,000.

  • [By Stephan Byrd]

    Murphy Oil Co. (NYSE:MUR) has earned an average rating of “Hold” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $31.56.

Top 10 Performing Stocks To Own Right Now: Gold Standard Ventures Corporation(GSV)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Gold Standard Ventures Corp (NYSEAMERICAN:GSV) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 6,511,796 shares, a drop of 7.7% from the April 30th total of 7,056,069 shares. Based on an average daily volume of 268,131 shares, the short-interest ratio is currently 24.3 days. Approximately 5.9% of the company’s stock are sold short.

Top 10 Performing Stocks To Own Right Now: GRAVITY Co. Ltd.(GRVY)

Advisors’ Opinion:

  • [By Cooper Creagan]

    For example, if you had taken five minutes to set up a Night Trade on Gravity Co. (Nasdaq: GRVY) in October, you could’ve tripled your money, and then some.

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Gravity (GRVY) Receives Coverage Optimism Score of 0.17” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at www.tickerreport.com/banking-finance/3382037/gravity-grvy-receives-coverage-optimism-score-of-0-17.html.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Gravity (NASDAQ:GRVY) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday morning.

Top 10 Performing Stocks To Own Right Now: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By Shane Hupp]

    Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.

  • [By Stephan Byrd]

    Trexquant Investment LP acquired a new position in Sarepta Therapeutics (NASDAQ:SRPT) in the first quarter, Holdings Channel reports. The institutional investor acquired 7,135 shares of the biotechnology company’s stock, valued at approximately $529,000.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    Three biotech stocks — Solid Biosciences (NASDAQ:SLDB), Sarepta Therapeutics (NASDAQ:SRPT), and Heron Therapeutics (NASDAQ:HRTX) — soared this week by 30% or more thanks to news that brought smiles to investors’ faces. Here’s what drove these stocks higher and whether or not they’resmart picks to buy now.

  • [By Chris Lange]

    Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy (DMD) trial. Specifically, the results came from Sareptas Phase 1/2a gene therapy clinical trial assessing AAVrh74.MHCK7.micro-Dystrophin in individuals with DMD.

  • [By Logan Wallace]

    Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.

Top 10 Performing Stocks To Own Right Now: Saul Centers, Inc.(BFS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Teachers Insurance & Annuity Association of America purchased a new position in shares of Saul Centers, Inc. (NYSE:BFS) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 13,437 shares of the real estate investment trust’s stock, valued at approximately $685,000. Teachers Insurance & Annuity Association of America owned approximately 0.06% of Saul Centers at the end of the most recent quarter.

  • [By Logan Wallace]

    Shares of Saul Centers, Inc. (NYSE:BFS) have been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $54.50.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Saul Centers (BFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Saul Centers (BFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *